Related Experiment Videos

Recent advances in 1,3,5-triazine-based PI3K inhibitors for cancer therapy: a comprehensive review

Utkarsha Kulkarni1, Adarsh Yadav1, Princy Desai1

  • 1Department of Pharmaceutical Chemistry, Parul Institute of Pharmacy, Parul University, Vadodara, India.

Future Medicinal Chemistry
|July 4, 2026
PubMed

Insights

Selective 1,3,5-triazine (s-triazine) inhibitors show promise for targeting the PI3K-AKT/mTOR pathway in cancer. Advances in medicinal chemistry optimize potency and selectivity, but pharmacokinetic issues and resistance remain challenges for clinical translation.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • The phosphatidylinositol-3-kinase (PI3K)-AKT/mTOR pathway is crucial in cancer development and treatment resistance.
  • Targeted therapies are needed to address the rising global and Indian cancer burden.

Purpose of the Study:

  • To review recent advances (2021-2025) in the design of selective PI3K inhibitors utilizing the 1,3,5-triazine (s-triazine) scaffold.
  • To highlight structure-activity relationship (SAR) optimization strategies and identify key design principles for improved efficacy.

Main Methods:

  • Analysis of medicinal chemistry literature and biological data for various triazine chemotypes.
  • Evaluation of structure-activity relationships (SAR) and molecular modeling (docking/MD simulations).

Main Results:

  • Convergent design rules identified: heteroaryl/aminopyrimidine hinge binders, hydrophobic pocket-filling groups, and polar solvent-exposed moieties (e.g., morpholine) enhance potency and selectivity.
  • Representative compounds induce cell cycle arrest and apoptosis via PI3K-AKT pathway inhibition.
  • Key interactions with amino acid residues Val851, Asp810, Lys802, and Gln859 were frequently observed.

Conclusions:

  • The s-triazine scaffold offers a versatile platform for developing potent and selective PI3K inhibitors.
  • Overcoming pharmacokinetic limitations, resistance mechanisms, and isoform-specific toxicities is critical for clinical translation.
  • Future strategies include rational isoform targeting, multitarget designs, ADME optimization, and AI-driven SAR modeling.
Keywords:
PI3KPI3K/mTOR inhibitorsanticancer drug discoverys-triazinetargeted therapy

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...